Guidance

1.1 Current evidence on the efficacy and safety of infracoccygeal sacropexy using mesh for vaginal vault prolapse repair is inadequate in quantity and quality. Therefore this procedure should only be used with special arrangements for clinical governance, consent and audit or research.

1.2 Clinicians wishing to undertake infracoccygeal sacropexy using mesh for vaginal vault prolapse repair should take the following actions:
   - Inform the clinical governance leads in their Trusts.
   - Ensure that patients understand the uncertainty about the procedure's safety, including mesh erosion (for example, into the vagina) and the risk of recurrence, and provide them with clear written information. In addition, use of NICE’s information for patients ('Understanding NICE guidance') is recommended (available from www.nice.org.uk/IPG281publicinfo).

1.3 The procedure should only be carried out by surgeons specialising in the management of pelvic organ prolapse and female urinary incontinence.

1.4 The British Society for Urogynaecology runs a database on urogynaecological procedures, and clinicians should enter details about all patients undergoing this procedure onto this database (www.bsug.net).

1.5 NICE encourages further research into infracoccygeal sacropexy using mesh for vaginal vault prolapse repair, and may review the procedure on publication of further evidence on different types of mesh. Clinicians are encouraged to collect long-term data on clinical outcomes and patient-reported quality-of-life outcomes using validated scales.

The procedure

2.1 Indications and current treatments

2.1.1 Vaginal vault prolapse can occur in women who have had a hysterectomy. The uppermost part of the vagina descends from its normal position, sometimes out through the vaginal opening. It can affect quality of life by causing symptoms of pressure and discomfort, and by its effect on urinary, bowel and sexual function.

2.1.2 Current treatment options include pelvic floor muscle training, use of pessaries and surgery. Several surgical procedures can be used, including hysterectomy, mesh sacrocolpopexy, uterine suspension sling (including sacrohysteropexy) and uterine/vault suspension (without sling). Some of these procedures involve the use of mesh, with the aim of providing additional support.

2.2 Outline of the procedure

2.2.1 The procedure is performed with the patient under general anaesthesia. An incision is made in the posterior wall of the vagina and a small puncture incision is made in each buttock. A tape (mesh) is introduced through one buttock and, using a tunnelling device (guided by a finger through the vaginal incision), the tape is passed around the rectum. The tape is then passed up the side of the vagina, across the top, and down...
2.2.2 This procedure can be combined with a hysterectomy or surgery for stress urinary incontinence, such as a suburethral sling placement.

2.2.3 Several different types of synthetic and biological mesh are available, which vary in structure and in their physical properties such as absorbability.

2.3 Efficacy

2.3.1 A case series of 93 women treated by infracoccygeal sacropexy reported subjective failure in 9% (8/91) of women (mean follow-up 12 months, 2 women lost to follow-up).

2.3.2 A case series of 75 women reported objective failure within 24 months in 10% (4/40) of women (35 patients lost to follow-up). A case series of 20 women reported no objective failure (0/20) at a mean follow-up of 16 months.

2.3.3 Case series of 93 and 75 women reported that 2% (2/91) and 30% (12/40) of women, respectively, had further surgery for vault prolapse with a mean follow-up of 12 months, and between 1 and 4.5 years, respectively.

2.3.4 The Specialist Advisers considered key efficacy outcomes to include success rates, as measured by the pelvic organ prolapse quantification system (POPQ), and outcomes including resolution of prolapse symptoms and urinary, bowel and sexual function. Three Advisers noted a need for long-term efficacy outcomes.

2.4 Safety

2.4.1 Rectal perforation was reported in 1% (1/93) and 3% (2/75) of patients in the case series of 93 and 75 women, respectively (subsequent management and follow-up not stated).

2.4.2 Mesh erosion was reported in 7% (2/30) of women treated by infracoccygeal sacropexy in a randomised controlled trial of 60 women (conference abstract only) at a mean follow-up of 24 months. Four case series of 93, 75, 52 and 15 women reported mesh erosion in 6% (6/93), 5% (4/75), 21% (11/52) and 7% (1/15) of women, respectively, at mean follow-up periods of between 20 weeks and 12 months.

2.4.3 Infection was reported in 5% (5/93) and 1% (1/75) of women (urinary tract infection and unspecified infection, respectively) within 1 week of surgery in the case series of 93 and 75 women, respectively.

2.4.4 The Specialist Advisers considered theoretical adverse events to include rectal injury, infection/sepsis, mesh erosion or rejection, dyspareunia and functional disturbance of the bowel or bladder. One Adviser commented that the development of new types of mesh means that current mesh-related complication rates may be lower than those available in the evidence.

3 Further information

3.1 NICE has published interventional procedures guidance on a number of procedures for uterine prolapse repair and vaginal vault prolapse repair. For more information go to www.nice.org.uk

Information for patients

NICE has produced information on this procedure for patients and carers (‘Understanding NICE guidance’). It explains the nature of the procedure and the guidance issued by NICE, and has been written with patient consent in mind. See www.nice.org.uk/IPG281publicinfo

Ordering printed copies

Contact NICE publications (phone 0845 003 7783 or email publications@nice.org.uk) and quote reference number N1771 for this guidance or N1772 for the ‘Understanding NICE guidance’.